Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin in 2nd-line Advanced NSCLC
NCT00252382Phase 2Completed
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Dec 2005
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosaroxin in non-small cell lung cancer (NSCLC), sponsored by Sunesis Pharmaceuticals, Inc. Primary endpoint: Objective Tumor Response Rate at 168 days. Started Dec 2005; status: completed.
02
Drugs
vosaroxin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00252382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252382.